



<u>RESPI-PROTECT - AN IMMUNOMODULATION APPROACH FOR PREVENTION</u> <u>AND TREATMENT OF RESPIRATORY INFECTIONS.</u>

Background:

Respiratory disease like Influenza, Coronavirus (SARS CoV2) lead to various disease in respiratory organs. These infections can cause viral pneumonia and acute respiratory distress syndrome (ARDS). A few vaccine/candidate compositions available comprise at least one or more live attenuated virus which may lead to restricted use. There is a need for formulations that can avoid restrictions and side effects and provide advantages associated with nasal administration.

Technology:

The proposed technology is an immunomodulatory protein-based immune-boosting mechanism with broad spectrum activity against all pathogens including viruses like Influenza and potentially COVID-19. It activates the innate immune system in the nasal mucosa, the initial entry point for respiratory pathogens, in a targeted manner through TLR2/4 pathways.

Applications:

First line preventative against Covid-19 and Influenza.

Advantages:

- Initiates protection within hours of application
- Possible Self-administered nasal spray/drop
- Being broad spectrum, can be used **against multiple respiratory infections** throughout the year.
- New, rapidly evolving mutants and VoCs of COVID-19 and Influenza could be addressed.

IP status:

PCT application filed on March 5, 2022: PCT/IB2022/051960 Application published. WO 2022/185286 A1. National Phase due in Sep/Oct 2023

